Abstract:

Objective　To investigate the influence of blood pressure factors onintravitreal injection of ranibizumab in the treatment of macular edema secondary to retinalvein occlusion. Methods　Retrospective analysis sixty-four patients (64 eyes) with hypertension combined with retinal vein obstruction secondary macular edema from January 2023 to December 2023 in Jinan Second People's Hospital, including 29 eyes with central retinal vein obstruction, 35 eyes with retinal branch vein obstruction. There were 30 males and 34 females,aged 41-81 years, with a course of 1-9 months. All patients were given intravitreal injection of ranibizumab 0.05 ml (0.5 mg) and medical consultation to intervene hypertension. According to the blood pressure control before operation, on the day of operation and at the time of review, they were divided into a blood pressure controlled group (17 cases), a blood pressure partially controlled group (29 cases), and a blood pressure uncontrolled group (18 cases). The best corrected visual acuity (BCVA) and macular fovea thickness were compared setween the three groups before and 1 day, 1 week, and 1 month after treatment. The numerical variable data were tested by one-way analysis of variance, and the categorical variable data were tested by chi-square test. Results　One month after treatment, the BCVA of the blood pressure controlled group and the blood pressure partially controlled group were 0.27±0.18 and 0.31±0.18, respectively, which were lower than 0.42±0.20 of the blood pressure uncontrolled group, and the difference was statistically significant (P<0.05). One week and one month after treatment, the macular foveal thicknesses in the blood pressure controlled group and the blood pressure partially controlled group [(311.45±40.03) μm, (328.11±43.15) μm, (301.25±40.88) μm, (319.56±43.76) μm] were smaller than those in the blood pressure uncontrolled group [(362.18±50.94) μm, (366.53±49.58) μm], and the differences were statistically significant (all P<0.05). Conclusions　That whether hypertension is controlled has a significant effect on the efficacy of intravitreal injection of ranibizumab in patients with macular edema secondary to retinal vein occlusion. Patients with good blood pressure control can obtain better vision and greater macular edema reduction.

Key words:

Retinal vein obstruction, Macular edema, Bood pressure, Visual acuity, Leizumab

摘要：

目的　探讨血压因素在玻璃体内注射雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿的影响。方法　回顾性分析，选取2023年1月至12月在济南市第二人民医院行玻璃体内注射雷珠单抗治疗高血压合并视网膜静脉阻塞继发黄斑水肿患者64例（64眼）作为研究对象，其中视网膜中央静脉阻塞29例，视网膜分支静脉阻塞35例，男30例、女34例，年龄41～81岁，病程1～9个月。所有患者均给予患眼玻璃体内注射雷珠单抗0.05 ml（0.5 mg），并内科会诊干预高血压，根据术前、手术日及复查时血压控制情况分为血压受控组（17例）、血压部分受控组（29例）与血压失控组（18例）。对比3组治疗前、治疗后1 d、1周、1个月最佳矫正视力（BCVA）及黄斑中心凹厚度。计量资料采用单因素方差分析，计数资料采用χ²检验。结果　治疗后1个月，血压受控组、血压部分受控组BCVA分别为0.27±0.18、0.31±0.18，均低于血压失控组的0.42±0.20，差异有统计学意义（P<0.05）。治疗后1周、治疗后1个月，血压受控组、血压部分受控组黄斑中心凹厚度［（311.45±40.03）μm、（328.11±43.15）μm、（301.25±40.88）μm、（319.56±43.76）μm］，均小于血压失控组［（362.18±50.94）μm、（366.53±49.58）μm］，差异均有统计学意义（均P<0.05）。结论　高血压是否受控，对玻璃体内注射雷珠单抗治疗的视网膜静脉阻塞继发黄斑水肿患者疗效影响显著，血压控制良好患者可获得较好视力和较大的黄斑水肿降幅。

关键词:

视网膜静脉阻塞, 黄斑水肿, 血压, 视力, 雷珠单抗